BioWorld MedTech

Oct. 5, 2018

Guardant prices $237.5M IPO above range, trades up almost 70 percent

It's not easy to pull off a major med-tech IPO, particularly for a diagnostics company. But Guardant Health Inc., which has staked a claim to being the leading liquid biopsy player, has priced its IPO to raise $237.5 million. Read More

Rare disease therapies delayed are promises broken, lives lost

Cambridge researcher planning to market artificial pancreas-related product

Medtronic launches Infinity OCT spinal system, sheds additional light on Mazor buy

Three win Chemistry Nobels for protein engineering methods

Other news to note

Daily M&A

Appointments and advancements

Financings

Product briefs

BioWorld MedTech's Diagnostics Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 27, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...